Emma Adhiambo Arigi

Title: Innovations in Glyco-engineering by Emma Adhiambo Arigi

Introduction

Emma Adhiambo Arigi is an accomplished inventor based in El Paso, TX (US). She has made significant contributions to the field of glyco-engineering, particularly in the development of plant-based platforms for the production of bioactive glycoproteins and cancer-specific vaccines. Her innovative work has the potential to revolutionize therapeutic approaches in medicine.

Latest Patents

Emma holds a patent titled "Methods for glyco-engineering plant cells for controlled human O-glycosylation." This invention discloses a novel platform for the recombinant production of bioactive glycoproteins and cancer-specific vaccines in plants. The technology humanizes plant cell cultures concerning human mucin-type protein O-glycosylation. The platform enables the production of a wide array of O-glycosylated human glycoprotein therapeutics, including human interferon α2B and podoplanin. It also allows for the engineering of additional cancer-specific O-glycans on glycoproteins of therapeutic value.

Career Highlights

Emma's career is marked by her innovative approach to using plant cells for human O-glycosylation. Her research has demonstrated that wild-type plant cells do not modify target peptide substrates, allowing for the introduction of human enzymes and substrates necessary for O-glycosylation. This groundbreaking work has established mucin-type O-glycosylation in plants through the introduction of specific human polypeptides and enzymes.

Collaborations

Emma has collaborated with notable colleagues, including Zhang Yang and Damian Paul Drew. These collaborations have further enhanced her research and contributed to the advancements in glyco-engineering.

Conclusion

Emma Adhiambo Arigi's innovative work in glyco-engineering represents a significant advancement in the field of biotechnology. Her contributions have the potential to lead to new therapeutic options for cancer treatment and other medical applications.